{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T08:25:42Z","timestamp":1792743942083,"version":"4.5.0"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:p>Endometrial carcinomas (EC) show variable HER2 protein expression or gene amplification and may be eligible for HER2-directed therapy (trastuzumab or antibody-drug conjugates (ADCs) such as trastuzumab-deruxtecan). HER2 testing is currently recommended in advanced-stage\/recurrent serous carcinomas and carcinosarcomas. However, no universally adopted reporting guidelines exist, and institutional practices vary. We aimed to analyze our experience with HER2 testing and compare gynecologic (GyC), gastric (GaC), and breast (BrC) criteria. We identified ECs with available HER2 immunohistochemistry (IHC) and fluorescence in-situ hybridization (FISH) results where applicable. HER2 IHC was reassessed using GyC, GaC, and BrC. The overall HER2-positivity rates were 31% by GyC and BrC, and 35.7% by GaC. The scoring systems significantly differed, with 69.8% concordance between GaC and GyC (<jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.001) and 99.2% concordance between BrC and GyC. Our results emphasize the importance of using the appropriate HER2 scoring criteria depending on the type of intended HER2-directed therapy as well as comprehensive yet perspicuous reporting of HER2 status to ensure optimal clinical outcomes in EC patients.<\/jats:p>","DOI":"10.1097\/pas.0000000000002392","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T20:35:56Z","timestamp":1743280556000},"page":"674-685","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Comparison of HER2 Scoring Systems in Endometrial Cancer"],"prefix":"10.1097","volume":"49","author":[{"given":"Ekaterina","family":"Menshikova","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Emory University Hospital, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Deeb","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Emory University Hospital, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Genega","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Emory University Hospital, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krisztina","family":"Hanley","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Emory University Hospital, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6125-5865","authenticated-orcid":false,"given":"Gulisa","family":"Turashvili","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Emory University Hospital, Emory University School of Medicine, Atlanta, GA"},{"name":"Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"key":"R2-20250618","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1097\/IGC.0000000000001050","article-title":"Clear cell carcinoma of the endometrium: evaluation of prognostic parameters in a multi-institutional cohort of 165 cases","volume":"27","author":"Abdulfatah","year":"2017","journal-title":"Int J Gynecol Cancer"},{"key":"R3-20250618","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1093\/annonc\/mdw161","article-title":"Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma","volume":"27","author":"Matsuo","year":"2016","journal-title":"Ann Oncol"},{"key":"R4-20250618","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.ejso.2010.09.010","article-title":"Prognostic factors in stages II\/III\/IV and stages III\/IV endometrioid and serous adenocarcinoma of the endometrium","volume":"36","author":"Mhawech-Fauceglia","year":"2010","journal-title":"Eur J Surg Oncol"},{"key":"R5-20250618","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"key":"R6-20250618","first-page":"8","article-title":"The role of HER2 as a therapeutic biomarker in gynaecological malignancy: potential for use beyond uterine serous carcinoma","volume":"55","author":"Karen","year":"2022","journal-title":"Pathology"},{"key":"R7-20250618","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41379-019-0358-x","article-title":"HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy","volume":"33","author":"Rottmann","year":"2020","journal-title":"Mod Pathol"},{"key":"R8-20250618","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3390\/cancers13010044","article-title":"HER2 status in high-risk endometrial cancers (PORTEC-3): relationship with histotype, molecular classification, and clinical outcomes","volume":"13","author":"Vermij","year":"2020","journal-title":"Cancers (Basel)"},{"key":"R9-20250618","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s00428-021-03017-5","article-title":"Histopathological features of HER2 overexpression in uterine carcinosarcoma: proposal for requirements in HER2 testing for targeted therapy","volume":"478","author":"Yoshida","year":"2021","journal-title":"Virchows Arch"},{"key":"R10-20250618","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/PGP.0000000000000783","article-title":"HER2 expression in endometrial cancers diagnosed as clear cell carcinoma","volume":"41","author":"Cagaanan","year":"2022","journal-title":"Int J Gynecol Pathol"},{"key":"R11-20250618","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1200\/JCO.2005.03.4827","article-title":"HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients","volume":"24","author":"Morrison","year":"2006","journal-title":"J Clin Oncol"},{"key":"R12-20250618","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1158\/1078-0432.CCR-20-0953","article-title":"Randomized phase ii trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress Her2\/Neu (NCT01367002): updated overall survival analysis","volume":"26","author":"Fader","year":"2020","journal-title":"Clin Cancer Res"},{"key":"R13-20250618","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","article-title":"Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu","volume":"36","author":"Fader","year":"2018","journal-title":"J Clin Oncol"},{"key":"R14-20250618","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/PAS.0000000000001870","article-title":"HER2 overexpression and amplification in uterine carcinosarcomas with serous morphology","volume":"46","author":"Jenkins","year":"2022","journal-title":"Am J Surg Pathol"},{"key":"R15-20250618","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1177\/10668969221102529","article-title":"The prognostic effect of HER2 gene amplification in high-grade endometrial carcinomas and its correlation with protein overexpression","volume":"31","author":"Bozkurt","year":"2023","journal-title":"Int J Surg Pathol"},{"key":"R16-20250618","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1200\/JCO.22.02558","article-title":"Trastuzumab deruxtecan for human epidermal growth factor receptor 2-expressing advanced or recurrent uterine carcinosarcoma (NCCH1615): the STATICE trial","volume":"41","author":"Nishikawa","year":"2023","journal-title":"J Clin Oncol"},{"key":"R18-20250618","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N Engl J Med"},{"key":"R19-20250618","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.annonc.2023.08.005","article-title":"HER2-low expression in patients with advanced or metastatic solid tumors","volume":"34","author":"Uzunparmak","year":"2023","journal-title":"Ann Oncol"},{"key":"R20-20250618","doi-asserted-by":"crossref","first-page":"e390772","DOI":"10.1200\/EDBK_390772","article-title":"Antibody-drug conjugates in gynecologic cancer","volume":"43","author":"Karpel","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"R21-20250618","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"R22-20250618","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-pantumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"R23-20250618","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"R24-20250618","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.5858\/arpa.2022-0229-CP","article-title":"Current laboratory testing practices for assessment of ERBB2\/HER2 in endometrial serous carcinoma and colorectal carcinoma","volume":"147","author":"Hagemann","year":"2023","journal-title":"Arch Pathol Lab Med"},{"key":"R25-20250618","first-page":"4","article-title":"HER2 status assessment in endometrial serous carcinoma: comparative analysis of two proposed testing and interpretation algorithms","volume":"43","author":"Hashem","year":"2024","journal-title":"Int J Gynecol Pathol"},{"key":"R26-20250618","doi-asserted-by":"crossref","first-page":"152184","DOI":"10.1016\/j.anndiagpath.2023.152184","article-title":"HER-2 overexpression in female genital tract clear cell carcinomas: Evaluation of different scoring guidelines, clinicopathological features and prognostic impact","volume":"66","author":"Edjtemaei","year":"2023","journal-title":"Ann Diagn Pathol"},{"key":"R27-20250618","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/modpathol.2013.113","article-title":"Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice","volume":"26","author":"Buza","year":"2013","journal-title":"Mod Pathol"},{"key":"R28-20250618","doi-asserted-by":"crossref","first-page":"687","DOI":"10.5858\/arpa.2020-0207-RA","article-title":"HER2 testing in endometrial serous carcinoma: time for standardized pathology practice to meet the clinical demand","volume":"145","author":"Buza","year":"2021","journal-title":"Arch Pathol Lab Med"},{"key":"R29-20250618","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/PGP.0000000000000711","article-title":"HER2 testing and reporting in endometrial serous carcinoma: practical recommendations for HER2 immunohistochemistry and fluorescent in situ hybridization: proceedings of the ISGyP companion society session at the 2020 USCAP annual meeting","volume":"40","author":"Buza","year":"2021","journal-title":"Int J Gynecol Pathol"},{"key":"R30-20250618","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"key":"R32-20250618","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1200\/JCO.22.02864","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-college of American pathologists guideline update","volume":"41","author":"Wolff","year":"2023","journal-title":"J Clin Oncol"},{"key":"R33-20250618","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2004.11.154","article-title":"Her-2\/neu overexpression and amplification in uterine papillary serous carcinoma","volume":"22","author":"Slomovitz","year":"2004","journal-title":"J Clin Oncol"},{"key":"R34-20250618","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ygyno.2005.03.041","article-title":"Determination of HER2\/neu status in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry and fluorescence in situ hybridization","volume":"98","author":"Santin","year":"2005","journal-title":"Gynecol Oncol"},{"key":"R35-20250618","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/00004347-199904000-00007","article-title":"HER-2\/neu amplification and overexpression in endometrial carcinoma","volume":"18","author":"Rolitsky","year":"1999","journal-title":"Int J Gynecol Pathol"},{"key":"R36-20250618","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1111\/j.1525-1438.2007.01181.x","article-title":"Serous carcinoma of the uterus-determination of HER-2\/neu status using immunohistochemistry, chromogenic in situ hybridization, and quantitative polymerase chain reaction techniques: its significance and clinical correlation","volume":"18","author":"Singh","year":"2008","journal-title":"Int J Gynecol Cancer"},{"key":"R37-20250618","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5858\/2007-131-18-ASOCCO","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer","volume":"131","author":"Wolff","year":"2007","journal-title":"Arch Pathol Lab Med"},{"issue":"suppl_16","key":"R38-20250618","first-page":"Abstract 3023","article-title":"Safety and efficacy of DB-1303 in patients with advanced\/metastatic solid tumors: a multicenter, open-label, first-in-human, phase 1\/2a study","volume":"41","author":"Kathleen","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000002392","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T21:00:18Z","timestamp":1750280418000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000002392"}},"subtitle":["Toward Optimization of HER2-Directed Therapies"],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000002392","relation":{},"ISSN":["0147-5185","1532-0979"],"issn-type":[{"value":"0147-5185","type":"print"},{"value":"1532-0979","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]}}}